GlassScriptPhysician profile
Daniel H Richter
NPI 1730246745
$3,566.25
in general payments reported to CMS, 2019-2025
32 companies · $78.43 in 2025
The $78.43 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $361 · 2020: $783 · 2021: $602 · 2022: $786 · 2023: $781 · 2024: $176 · 2025: $78.43.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,035.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,034.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $808.17 | 2019-2023 | Breztri, Farxiga, Fasenra |
| Lilly USA, LLC | $447.20 | 2019-2024 | Mounjaro, Jardiance, Emgality |
| Novo Nordisk INC | $385.21 | 2019-2024 | Rybelsus, Ozempic |
| Abbvie INC. | $278.29 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $265.66 | 2021-2024 | |
| Glaxosmithkline, LLC. | $155.01 | 2020-2023 | Shingrix, Arexvy |
| Merck Sharp & Dohme LLC | $146.28 | 2020-2022 | |
| Medicure Pharma INC. | $134.76 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $126.35 | 2019-2022 | |
| Amgen INC. | $100.26 | 2019-2023 | Repatha, Otezla |
| Astellas Pharma US INC | $85.19 | 2020-2023 | Veozah, Myrbetriq |
| Mylan Specialty L.P. | $84.39 | 2020-2023 | Yupelri |
| Pfizer INC. | $59.58 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $59.11 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $52.45 | 2022 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $42.83 | 2025 | Inspire |
| Gilead Sciences, INC. | $42.00 | 2019-2020 | |
| Teva Pharmaceuticals USA, INC. | $38.33 | 2021-2024 | Austedo Xr |
| Organon LLC | $35.04 | 2022-2023 | Nexplanon |
| Amarin Pharma, INC. | $31.57 | 2020 | |
| Otsuka America Pharmaceutical, INC. | $29.18 | 2023-2024 | Nuedexta, Rexulti |
| Sumitomo Pharma America, INC. | $22.33 | 2023 | Gemtesa |
| Dexcom, INC. | $18.41 | 2023 | Dexcom G6 Transmitter |
| Allergan, INC. | $15.75 | 2020 | |
| Sanofi-Aventis U.S. LLC | $15.40 | 2019 | |
| Bard Peripheral Vascular, INC. | $13.78 | 2025 | Peritx |
| Avanir Pharmaceuticals, INC. | $13.72 | 2021 | |
| Janssen Pharmaceuticals, INC | $13.07 | 2021 | |
| Novartis Pharmaceuticals Corporation | $12.48 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $12.12 | 2020 | |
| Ultragenyx Pharmaceutical INC. | $11.39 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $10.94 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Richter listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.